On Thursday, September 10, 2015: Shares of Horizon Pharma PLC (NASDAQ:HZNP), observed a gain of 0.53% and closed at $28.58.

Horizon Pharma plc, is truly a class in itself and is a specialty biopharmaceutical company that engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.

Horizon Pharma plc, declared that it has commenced mailing solicitation materials to Depomed, Inc. shareholders, counting a definitive solicitation statement formerly filed with the U.S. Securities and Exchange Commission on September 8, 2015 and a special letter, in connection with Horizon Pharma’s efforts to call two related special meetings of Depomed shareholders.

As formerly declared, on September 8, 2015, Horizon Pharma has also separately commenced an exchange offer to acquire all issued and outstanding shares of Depomed common stock. Under the terms of the exchange offer, each holder of Depomed common stock will have the right to receive 0.95 Horizon Pharma ordinary shares for each of their Depomed shares, which exchange ratio was based on a $33.00 per share offer price for Depomed stock and 15-day volume weighted average price of Horizon Pharma ordinary shares as of August 12th, 2015 of $34.74. The exchange offer, however, is conditioned on, among other things, the withdrawal or invalidation of Depomed’s poison pill noted below.

A copy of Horizon Pharma’s solicitation statement and special letter, in addition to the documents related to the exchange offer, are viewable at: www.HorizonAndDepomed.com, a website that Horizon Pharma launched to provide details and other relevant information regarding its proposals for the special meetings.

Notes to the Stakeholders:

This article is the intellectual property of www.jbhnews.com. The purpose of penning down this article has been just to share information. Moreover, it is firmly believed that all the information that are revealed in this article are from reliable sources, however, we do not make any representations or warranties whatsoever of any kind, express or implied, as far as the completeness, accurateness, or reliability with respect to this article is concerned.

All the respectable visitors to this website are kindly advised to conduct their own independent research into individual stocks prior to making a purchase decision.

This article contains an advanced information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as well as statements regarding the forseeable frequent growth of the market for the corporation’s products, the corporation’s capability to fund its capital requirement in the close-to term and in the long term; pricing pressures; etc.

Furthermore, any statement that expresses or involves discussions with respect to forecast, expectations, beliefs, strategy, projection, objectives, aims, assumption, or future events or performance may be forward looking statements. In addition, the forward-looking statements are wholly and solely based upon expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. An easy way to identify the forward looking statements is through the use of such words as be expecting, will, foresee, guess, considered, or by statements that indicates certain actions may, could, should/might occur.


Please enter your comment!
Please enter your name here